SENSEX 76070.84 (0.75)

Nifty 50 23581.15 (0.74)

Nifty Bank 54876 (0.85)

Nifty IT 28760.9 (-0.97)

Nifty Midcap 100 55174.4 (1.02)

Nifty Next 50 65021.6 (0.87)

Nifty Pharma 22597.55 (0.22)

Nifty Smallcap 100 15912.9 (0.65)

Indian Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Global Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
News
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
Metropolis Healthcare launches Centre of Genomics
(13 Jan 2026)
Metropolis Healthcare announced the launch of its Centre of Genomics, marking a significant step in scaling its long standing capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties.

Over the years, Metropolis has built a strong foundation in advanced genomics, with a particular focus on precision oncology anchored by its Global Reference Laboratory in Mumbai. Following the integration of Core Diagnostics' specialised genomics laboratory in the Delhi NCR region, these complementary capabilities have been unified to operate as CAP-accredited national referral laboratories for genomics, forming the backbone of the Centre of Genomics. This integrated model brings together a broad portfolio of NGS-based assays, robust bioinformatics and interpretation capabilities, and deep scientific and clinical expertise.

As part of the Centre's technology backbone, Metropolis has augmented its existing sequencing infrastructure with the deployment of Illumina's NovaSeq™ X Series for research purposes. The NovaSeq™ X system features Illumina's cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq™ X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what is possible in genetic sequencing, enabling users to unlock discoveries and advancements that were previously beyond reach.

Beyond the newly deployed NovaSeq™ X Series, the Centre of Genomics is supported by an existing, multi-platform NGS infrastructure already operational across Metropolis' key genomics hubs. The Centre of Genomics brings together multidisciplinary teams of molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful insights for patient care.